Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy

doi:10.1136/bmj.313.7071.1554c

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Michel Marre,
Gilles Chatellier,
Francois Alhenc-Gelas

Professor of therapeutics Medecine B, Centre Hospitalier Universitaire, 49033 Angers, France
Senior registrar Service d'Informatique Medicale, Hopital Broussais, 75014 Paris, France
Director INSERM Unite 367, 75005 Paris

EDITOR,—Hans-Henrik Parving and colleagues report that patients with diabetic nephropathy who were homozygous for a deletion polymorphism of the angiotensin converting enzyme gene progressed more rapidly towards renal failure than did other diabetic patients with diabetic nephropathy once glycaemic control was controlled for in their analysis.1 This is consistent with the results of a study that we published two years ago2 but contrasts with a previous report from the same group.3

There are two possible reasons for the discrepancy between …